HIMS Hims & Hers Health, Inc. Insider Trading

HIMS CMO Patrick Harrison Carroll sold 23,726 shares at $35.00 (total $830.4K); post-sale holdings 181.9K shares via scheduled 10b5-1 plan.

Patrick Harrison Carroll, Chief Medical Officer of Hims & Hers Health, Inc., executed a scheduled sale of 23,726 shares at $35.00 per share on 2026-06-18 under a pre-arranged 10b5-1 trading plan. The sale reduced his holdings by 11.5% from 205,587 shares to 181.9K shares. Since this transaction is part of a 10b5-1 plan, it is scheduled and automatic rather than a discretionary trade reflecting real-time market judgment. At current price $32.96, the stock is -53.2% from its 52-week high of $70.43, though it has appreciated 38.8% over the past 30 days and 58.2% over the past 90 days. Notably, Carroll's same-ticker history at HIMS shows mixed outcomes: his September 2025 sale was followed by -1.4% (30d) and -27.0% (90d) returns, while his August 2025 sale preceded -9.6% (30d) and -20.1% (90d) results, suggesting prior HIMS sales have not consistently aligned with subsequent stock performance. The company reported revenue of $608.1M with net income of -$92.1M in the latest quarter, alongside 59.0% annual revenue growth, indicating strong top-line momentum despite current profitability challenges.

CFO Oluyemi Okupe sold 18.2K shares of HIMS at $34.03 under 10b5-1 plan; holds 284.3K shares post-trade plus 109,524 options.

Oluyemi Okupe, CFO of Hims & Hers Health, Inc., sold 18,197 shares at $34.03 on 2026-06-22 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-05-21, reducing his non-derivative holdings by 6.0% to 284,321 shares while retaining 109,524 shares in stock options. The transaction is scheduled rather than discretionary. His prior sales at this ticker show mixed outcomes: the 30-day change following this filing's scheduled execution occurs during a period when HIMS has gained 38.8% over the last 30 days, though the stock remains 53.2% below its 52-week high of $70.43. The company's latest quarter shows $608,104,000 in revenue and a net loss of $92,115,000, with annual revenue growth of +59.0% year-over-year, indicating growth amid current unprofitability.

CTO Mohamed Elshenawy sold 30,040 shares of HIMS at $31.50 under 10b5-1 plan; holds 101.0K shares post-sale.

Mohamed Elshenawy, CTO of Hims & Hers, executed a scheduled sale of 30,040 shares on 2026-06-17 at $31.50 per share under a pre-arranged 10b5-1 trading plan adopted 2025-12-01, reducing his non-derivative holdings from 131.1K to 101.0K shares. The transaction was systematic and predetermined rather than discretionary, meaning timing was not a factor in the trade decision. The current stock price of $31.89 sits -54.7% from the 52-week high of $70.43, while the company reported quarterly revenue of $608.1M with a net loss of $-92.1M and annual revenue growth of +59.0%. The insider maintains substantial derivative holdings of 1,129,964 shares through restricted stock units, indicating continued material stake in the company despite the non-derivative share reduction.

Director David B Wells purchases 48,400 HIMS shares at $24.24 for $1,172,974.00; holdings rise 27.5% to 224,417 shares

David B Wells, a Director of Hims & Hers Health, purchased 48,400 shares at $24.24 on 2026-05-26 in an open-market transaction totaling $1,172,974.00, increasing his holdings by 27.5% to 224,417 shares. The purchase occurs against mixed fundamentals: Hims reported $608,104,000.00 in latest-quarter revenue with strong 59.0% annual growth, yet recorded a net loss of $-92,115,000.00. His prior trading at HIMS shows 2 completed sells (on 2024-11-13 and 2024-02-28) that both posted substantially positive 90-day returns (+45.3% and +45.2% respectively), indicating poorly-timed exits that missed significant post-sale gains. The buy transaction itself is material in size relative to his historical trading activity and represents a discrete accumulation gesture in a growth-stage healthcare company operating at net loss.

CFO Okupe Oluyemi sold 19,645 shares of HIMS at $29.96 under pre-arranged 10b5-1 plan; retains 262,954 shares.

Okupe Oluyemi, CFO of Hims & Hers Health, Inc., executed a sale of 19,645 shares at $29.96 on 2026-04-20 under a pre-arranged 10b5-1 trading plan adopted on 2025-05-21. This is a scheduled, non-discretionary transaction governed by the plan, so the timing reflects plan mechanics rather than active decision-making around current market conditions. Post-transaction, his holdings remain substantial at 262,954 shares, representing a -7.0% reduction from the prior level of 282,599 shares. The transaction reduced his position but did not exit the company; continued significant equity ownership by the CFO is an observable fact for investors assessing management stake alignment.

CFO Okupe Oluyemi sells 54,927 HIMS shares for $1,457,305.25 via scheduled 10b5-1 plan

Okupe Oluyemi, CFO of Hims & Hers Health, executed 2 separate sales totaling 54,927 shares for $1,457,305.25 across April 16–17, 2026, at prices ranging from $25.90 to $27.83 per share. This sale was conducted under a 10b5-1 trading plan adopted on 2025-05-21, meaning the transactions were scheduled in advance rather than discretionary. Post-transaction, Oluyemi held 270,046 shares, representing a 16.9% reduction from the prior holding of 324,973 shares. As a scheduled plan execution, the sale reflects predetermined liquidity or portfolio management rather than a real-time response to company developments or market conditions.

Chi Michael, then-COO, sold 97,289 HIMS shares at $24.69 under pre-arranged 10b5-1 plan; retains 407,282 shares

Chi Michael, who was COO at the time of the transaction, sold 97,289 shares (19.3% of pre-transaction holdings) at $24.69 on 2026-03-17 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-04. Because this sale was scheduled under a 10b5-1 arrangement rather than discretionary, it reflects a contractual selling schedule established months earlier and does not signal timing-based confidence or concern at the sale date. The transaction reduced his position to 407,282 shares, meaning he retains material equity exposure to the company.

CFO Okupe Oluyemi sold 23,090 shares of HIMS at $35.72 under pre-arranged 10b5-1 plan

Okupe Oluyemi, Chief Financial Officer of Hims & Hers Health, Inc., sold 23,090 shares at $35.72 on 2025-12-22, reducing his holdings from 117,423 shares to 94,333 shares. This transaction was executed under a 10b5-1 trading plan adopted on 2025-05-21, meaning the sale was scheduled in advance and not discretionary. The 19.7% reduction in holdings reflects a scheduled divestiture with no signal regarding current conviction or market outlook, as the timing and volume were determined months prior to execution.

Then-COO Chi Michael sells 13,750 HIMS shares at $36.71 under pre-arranged 10b5-1 plan

Chi Michael, who was Chief Operating Officer at the time of filing, sold 13,750 shares (305.2K shares post-transaction, representing a 4.3% reduction from prior holdings) at $36.71 per share for total value of $504,762.50 on 2025-12-17. This sale was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-03-04, meaning it was scheduled and not a discretionary decision. Since the transaction follows a pre-arranged plan rather than a reactive market decision, it provides limited signal about current insider sentiment or market timing judgment specific to this moment. The sale reduces his holdings but maintains a substantial 305.2K-share position.

HIMS CFO Okupe sells 23,187 shares (23.2K) at $36.81 under pre-arranged 10b5-1 plan; post-transaction holdings 70,232 shares

Okupe Oluyemi, HIMS Chief Financial Officer, executed a sale of 23,187 shares at $36.81 on 2025-11-17 under a 10b5-1 trading plan adopted on 2025-05-21, reducing his holdings from 93,419 shares to 70,232 shares. The transaction represents a 24.8% reduction in holdings and generated approximately $853,490.28. As a pre-arranged and scheduled transaction under Rule 10b5-1, this sale reflects contractual execution rather than a discretionary trade decision, and therefore does not convey timing-based market signals about insider confidence at this price.